Evaluation of a combination drug with multiple doses in unbalanced factorial design clinical trials
1Division of Biometrics I, Office of Biostatistics, CDER, FDA, HFD-710, Room 5062, Woodmont II, 1451 Rockville Pike, Rockville, MD 20852, USA. hung@cder.fda.gov
Abstract:
Flexibilities for sample size allocation are often demanded for achieving multiple study objectives in combination drug trials. The global tests of Hung, Chi and Lipicky are extended for analysis of unbalanced factorial design trials to test the hypothesis that at least one of the non-zero dose combinations of two drugs is more effective than the respective component doses. When the dose combinations have heterogeneous effect sizes, an unbalanced design may induce greater power than the balanced design. An adjusted p-value approach is proposed for testing the individual dose combinations under the condition that the maximum type I error probability is protected.
Related Concept Videos
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Clinical Trials: Overview
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Dosage Regimens: Designs and Approaches
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses


